Aviva’s Amneal Pharmaceuticals AMRX Stock Holding History

Aviva’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-25,078	Closed	-$316K	–	850
2025 Q4	$316K	Buy	+25,078	New	+$287K	﹤0.01%	852

Other funds holding AMRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Aviva's AMRX Position: Q1 2026 in Review

Aviva sold out of Amneal Pharmaceuticals (AMRX) in Q1 2026, closing a stake of 25,078 shares — an estimated $316K sold.

Aviva first reported a position in AMRX in Q4 2025 and held it in 1 quarter. The position peaked at $316K in Q4 2025. 315 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

Aviva reported no remaining Amneal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Aviva sold 25,078 Amneal Pharmaceuticals shares in Q1 2026, an estimated $316K.
Aviva first reported a position in Amneal Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Aviva's Amneal Pharmaceuticals position peaked at $316K in Q4 2025.
315 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Aviva's 13F filing for Q1 2026, filed 14 May 2026.